A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations ("Off Episodes")

Trial Profile

A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations ("Off Episodes")

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Levodopa (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Acorda Therapeutics; Civitas Therapeutics
  • Most Recent Events

    • 13 Oct 2016 Results from this and phase I trials of CVT-301 published in the Scince Tanslation Medicine, according to an Acorda Therapeutics.
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 19 Apr 2013 Top-line results have been reported in a Civitas Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top